Genetically modified TCRs for cancer immunotherapy.

Slides:

Advertisements

Similar presentations

Antigen Presentation K.J. Goodrum Department of Biomedical Sciences Ohio University 2005.

Advertisements

Chimeric antigen receptors (CAR)

Understanding biology through structuresCourse work 2006 Understanding Immune Recognition.

115/9/2015 T Cell Receptor Hugh B. Fackrell Nov 9, 1998.

Structure of T Cell Receptor CHO Variable region “V” Constant region “C” Hinge “H ” Alpha chain Beta chain Disulfide bridge Transmembrane region Cytoplasmic.

1 How T cells recognize antigen: The T Cell Receptor (TCR) Lecture 11, MCB 150 Laurent Coscoy.

Antigen Receptors of Lymphocytes. Recognition: molecular patterns Recognition : molecular details (antigenic determinants) Innate immunity Aquired immunity.

Janeway’s Immunobiology

T Cells Lacey Jeong. What is a T Cell?? Thymus cell – produced and processed by the thymus gland Lymphocyte (white blood cell) – protect body from infection.

A novel naturally occurring splice variant of the human TGF-β type II receptor (TβRII) encodes a truncated soluble molecule M S Bertolio1; T M Rodriguez1;

Chapter 43 The Immune System.

Adaptive immunity antigen recognition Y Y Y Y Y Y Y Y Y invading

The Principles of Engineering Immune Cells to Treat Cancer

Socializing Individualized T-Cell Cancer Immunotherapy

Volume 12, Issue 5, Pages (November 2005)

Recognition of Antigen By T cells: The TCR

chimeric antigen receptor T-cell therapy for ALL

The Major Histocompatibility Complex (MHC)

Professor John Gribben Barts Cancer Institute

Soluble T Cell Receptor (scTCR) Creative Biolabs scientists are discovering and manufacturing more immunological reagents, which is one of the largest.

TCR RECEPTORS Main receptors -αβ(Alpha &beta) - γδ(Gamma& delta)

Jacques F.A.P. Miller, Michel Sadelain Cancer Cell

Immunogenetics Lecture 3: TcR.

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

The Differentiation of Vertebrate Immune Cells

Research Techniques Made Simple: CAR T-Cell Therapy

Figure 1 Chimeric antigen receptor (CAR) structures

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

Molecular Therapy - Oncolytics

Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?

Nat. Rev. Clin. Oncol. doi: /nrclinonc

CAR T cell therapy—principle and clinical trial overview

Figure 5 Classification of immunotherapies

Co-Receptors: Function

CAR T cell therapy—principle and clinical trial overview

Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care? Arjan C. Lankester, Franco Locatelli, Peter Bader, Eva Rettinger,

Figure 1 CAR-T-cell design

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Nat. Rev. Urol. doi: /nrurol

Applications of Immunogenomics to Cancer

Daniel Abate-Daga, Marco L Davila Molecular Therapy - Oncolytics

Figure 3 Structure of different types of T-cell-engaging antibodies

Miki Ando, Hiromitsu Nakauchi Experimental Hematology

The Major Histocompatibility Complex (MHC)

Figure 2 Site of action of checkpoint inhibitors and agonists being

Titratable control of engineered therapeutic T cells through an ON-switch chimeric antigen receptor. Titratable control of engineered therapeutic T cells.

Nat. Rev. Endocrinol. doi: /nrendo

The Other Face of Chimeric Antigen Receptors

Volume 3, Issue 5, Pages (May 2003)

Research Techniques Made Simple: CAR T-Cell Therapy

The Principles of Engineering Immune Cells to Treat Cancer

Figure 1 Mechanisms of action of immunotherapy modalities

T cell receptor complex and diversity

New Cell Sources for T Cell Engineering and Adoptive Immunotherapy

Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse Saad S. Kenderian, David L. Porter,

Chimeric antigen receptor T-cell therapy for solid tumors

Forward and reverse genetic approaches in Drosophila.

SLE: the many players involved in systemic autoimmunity and tissue destruction. SLE: the many players involved in systemic autoimmunity and tissue destruction.

Manufacturing and delivery pipeline of genetically modified T-cell therapies. Manufacturing and delivery pipeline of genetically modified T-cell therapies.

Cells of the innate and adaptive immune systems.

CD8+ T-cell subsets. CD8+ T-cell subsets. There are a number of different CD8+ T-cell subsets. Naïve, T stem cell (TSCM) and T central memory (TCM) cells.

Gene targeting: Applications in transplantation research

Releasing the Brakes on Cancer Immunotherapy

WT MARCH8, but not the CS mutant, specifically ubiquitinates and downregulates TfR. WT MARCH8, but not the CS mutant, specifically ubiquitinates and downregulates.

Fig. 1 Engineered T cells: design of TCR versus CAR T cells.

CAR T cell immunotherapy for human cancer

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer?

Chimeric antigen receptor–modified T cells: CD19 and the road beyond

Presentation transcript:

Genetically modified TCRs for cancer immunotherapy. Genetically modified TCRs for cancer immunotherapy. (A) T-cell response can be manipulated and redirected against cancer, with improved specificity and affinity for tumour antigens, via genetic engineering of the endogenous TCR. (B) Genetically modified TCR: gene sequences are transferred to the T cell to encode new TCR α and β chains with different peptide specificity. In addition, there can also be transmembrane changes (red bars). To minimise interchain mispairing with the endogenous TCR, modifications such as the addition of a disulphide bridge (ss) are made. (C) Alternatively, a fusion receptor can be generated, a chimeric antigen receptor (CAR). Typically, these consist of three parts: a recognition sequence [represented here by an antibody-derived single-chain variable fragment (scFv)], a transmembrane element and an intracellular bespoke signalling domain (CD3ζ), which also contains co-stimulatory molecules, such as CD28 and tumour necrosis factor receptors (TNFr) such as OX-40. Michaela Sharpe, and Natalie Mount Dis. Model. Mech. 2015;8:337-350 © 2015. Published by The Company of Biologists Ltd